Phase 3
To alleviate the problem of antibiotic-resistant bacteria, or superbugs, several biotechnology companies are developing different strategies to target and kill these microorganisms.
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.
The company’s vision for the next few years includes annual revenue of $5 billion by 2025 and the approval of at least five novel products by the end of the decade.
Vaccine development is experiencing a resurgence in the wake of the COVID-19 pandemic, with companies developing a variety of approaches.
Looking at long-term growth, Michael said that will be driven by numerous differentiated assets across each of Abbvie’s core areas.
Adagio cited three recent independent, in vitro studies showing that ADG20, which is currently undergoing Phase II/III clinical trials, has neutralization activity against Omicron.
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
The job cuts were announced as part of an organizational streamlining initiative that will refocus resources toward the company’s highest-value activities.
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
Sarepta Therapeutics shared positive topline results from its ongoing SRP-9001-102 study on the effectiveness of delandistrogene moxeparvovec in treating Duchenne muscular dystrophy.
PRESS RELEASES